Axonal Sensory Neuropathies with Serum IgM binding to Trisulfated Heparin Disaccharide (TS-HDS)
Immune/Antibody
W
View full entry on WUSTL Neuromuscular
antibody/pnimax.html#Axonal Sensory Neuropathies with Serum IgM binding to Trisul
Overview
From WUSTL NeuromuscularEpidemiology Frequency Sensory neuropathies: 10% to 20% Small fiber sensory neuropathies: 37% Acute onset small fiber sensory neuropathies: 80% to 90% Sex: Female > Male TS-HDS: Most common neuropathy-related IgM MGUS antibody TS-HDS Disaccharide Component of glycosylation of: Heparin & Heparan sulfate Hereditary Heparan sulfate-related neuropathy: NAGLU Clinical Onset Age: Mean 60 years; Range 7 to 83 years Acute onset: More frequent than antibody negative patients Sensory loss (100%) Distal predominant Symmetric: 90% Modalities Small fiber (Pin): All Vibration: Loss 57%; Absent at toes 17% P
Related Conditions
Shared genesAntibodies vs Glycolipids & Glycoproteins
GM1MAGGQ1B
CHRONIC IMMUNE POLYNEUROPATHIES: AXONAL
HDS
I. Clinical Indications for Measurement of anti-MAG antibodies
MAG
II. Results with Specificity and Sensitivity for Sensory-Motor Neuropathies
MAG
III. Testing Laboratory Standards for anti-MAG Antibodies.
MAG
IV. Interpretations of Confirmed Positive anti-MAG Results
MAG
IV. Positive Result: Clinical Utility and Interpretations
MAG
Monoclonal Gammopathies of Unknown Significance (& Other)
MAGGD1AHDS
External Resources
Data sourced from the Washington University Neuromuscular Disease Center. For clinical use, always refer to primary sources.